Plexision
Company Details
Status: Private
Employees: 1-10
Location:
Pittsburgh, Pennsylvania, United States
Type:
sample
sample
Technology:
sample
sample
About: Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation, and immunological disorders.
Plexision's first patented product, the PleximmuneTM assay, predicts the risk of transplant rejection. The test is based on patent-pending technology to measure antigen-specific white blood cells.
Testing services for transplant recipients and drug developers are provided at Plexision's CLIA-certified, central laboratory in Pittsburgh.
Plexision currently offers cell-based testing for personalized assessment of rejection risk after solid organ transplantation The Pleximmune blood test is the first such test offered for children with liver or intestine transplantation.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Plexision | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.